hsa_circ_0136666, PRKDC, and Immune Escape in Gastric Cancer

Study Background and Research Question

Gastric cancer remains a leading cause of cancer mortality globally, with limited effectiveness of current therapies due to late diagnosis, drug resistance, and tumor immune evasion. As immune checkpoint inhibitors such as anti-PD-L1 antibodies increasingly enter clinical use, understanding the mechanisms behind tumor immune escape is vital for improving therapeutic outcomes. Circular RNAs (circRNAs), a class of covalently closed non-coding RNAs, have emerged as key regulators in cancer biology, often functioning as microRNA (miRNA) sponges and modulators of gene expression. Prior studies have implicated both circRNAs and their target miRNAs in tumorigenesis, but the precise molecular circuits enabling immune escape in gastric cancer have remained unclear.

Key Innovation from the Reference Study

Miao et al. (Molecular Cancer 2023) provide a mechanistic dissection of how the circRNA hsa_circ_0136666 orchestrates tumor progression and immune evasion in gastric cancer. Their work demonstrates that hsa_circ_0136666 acts by sponging miR-375-3p, thereby upregulating PRKDC (the gene encoding DNA-PKcs, a key kinase in DNA repair and signaling). This, in turn, enhances phosphorylation of PD-L1, stabilizing the immune checkpoint protein and promoting its aggregation at the tumor cell surface, which contributes to immune escape. The study thus uncovers a direct circRNA–miRNA–protein kinase–immune checkpoint regulatory axis, linking DNA repair pathways and tumor immunology in a novel way.

Methods and Experimental Design Insights

The authors employed a combination of molecular and cellular assays to unravel this regulatory axis:

• Expression Profiling: Quantitative RT-PCR and fluorescence in situ hybridization (FISH) were used to assess hsa_circ_0136666 and miR-375-3p levels in gastric cancer tissues and cell lines compared to controls.
• Functional Assays: Western blotting and ELISA quantified PRKDC and PD-L1 protein levels and phosphorylation status. Flow cytometry evaluated immune cell populations, particularly CD8+ T cell activity in tumor-bearing mice.
• Mechanistic Probing: Reporter assays, RNA immunoprecipitation, and mutational analyses confirmed direct binding between hsa_circ_0136666 and miR-375-3p, as well as miR-375-3p’s regulation of PRKDC.
• In Vivo Models: Tumor xenograft mouse models assessed the effects of hsa_circ_0136666 modulation and the combinatory impact of siRNA strategies alongside anti-PD-L1 therapy.

This multifaceted approach allowed the team to map the pathway from circRNA expression to immune checkpoint stabilization and immune evasion.

Core Findings and Why They Matter

The central findings of the study are as follows:

• Overexpression of hsa_circ_0136666: This circRNA is highly expressed in gastric cancer tissues and cell lines, correlating with tumor proliferation and aggressiveness.
• miR-375-3p as a Tumor Suppressor: Downregulation of miR-375-3p releases its repression of PRKDC, a key player in DNA repair and cell survival.
• PRKDC Upregulation: Elevated PRKDC promotes the phosphorylation of PD-L1, protecting the checkpoint protein from degradation and increasing its accumulation on the tumor surface.
• Immune Escape Mechanism: The stabilized, phosphorylated PD-L1 impairs CD8+ T cell-mediated immune responses, facilitating tumor immune evasion.
• Therapeutic Implications: Silencing hsa_circ_0136666 via LNP-siRNA not only reduced tumor growth but also enhanced the efficacy of anti-PD-L1 antibodies in preclinical models, pointing to a potential combinatory strategy for overcoming resistance to checkpoint blockade.

Collectively, these findings elucidate how a non-coding RNA can interface with DNA repair signaling and immune checkpoint regulation, providing new therapeutic entry points for gastric and possibly other cancers.

Comparison with Existing Internal Articles

The pivotal role of PRKDC (DNA-PKcs) in both DNA repair and immune regulation anchors this study in a broader landscape of DNA damage response (DDR) research. Several internal resources and reviews have highlighted the utility of selective DNA-PK inhibitors such as NU7441 (KU-57788) in dissecting DDR pathways and sensitizing cancer cells to DNA-damaging agents. For instance, NU7441’s nanomolar selectivity and high specificity for DNA-PK have enabled detailed analysis of cell cycle arrest and apoptosis in various cancer models. Other in-depth analyses, such as thought-leadership articles, further discuss how DNA-PK inhibition intersects with translational research in oncology and neurodegeneration.

This reference study extends these insights by demonstrating that DNA-PKcs (PRKDC) also regulates immune checkpoint stability, linking the canonical DDR machinery to tumor immune evasion. The integration of circRNA regulation into this axis is a unique contribution not previously emphasized in the DNA repair or oncology research literature.

Limitations and Transferability

While the study provides compelling evidence for the hsa_circ_0136666/miR-375/PRKDC/PD-L1 axis in gastric cancer, several limitations must be considered:

• Context-dependence: The findings are specific to gastric cancer models; further validation in other tumor types is needed to establish broader relevance.
• Preclinical Stage: The therapeutic effects of LNP-siRNA and anti-PD-L1 combinations were demonstrated in animal models; clinical translation will require additional safety and efficacy studies.
• CircRNA Complexity: CircRNAs often have multiple targets and interactors; off-target effects or redundant pathways might attenuate the impact of targeting a single circRNA in the clinic.

Nonetheless, the study’s mechanistic clarity makes it a valuable foundation for future translational research.

Protocol Parameters

• In vitro knockdown: Use siRNA targeting hsa_circ_0136666 in gastric cancer cell lines for 24-48 h to assess downstream effects on miR-375-3p, PRKDC, and PD-L1 levels.
• Cell cycle and apoptosis assays: Apply DNA-PK inhibition (e.g., 1 μM for 16 h) to probe cell cycle arrest and immune response modulation in the context of circRNA or miRNA perturbation.
• In vivo studies: For xenograft models, administer LNP-siRNA via tail vein and/or combine with anti-PD-L1 antibody dosing according to established regimens.

Research Support Resources

For researchers aiming to interrogate the DNA damage response pathway or to model the effects of DNA-PKcs inhibition in oncology research, NU7441 (KU-57788) DNA-PK inhibitor (SKU A8315) is a validated tool compound. With high selectivity and robust potency, it enables precise modulation of DNA-PK activity in cell cycle arrest assays and studies of immune checkpoint regulation. Protocols typically employ 1 μM in vitro for up to 16 hours, or 10 mg/kg via intraperitoneal injection in mouse models, as recommended in the product information. APExBIO provides formulation and storage guidance to maintain compound stability, supporting reliable DNA repair research and cancer signaling experiments.